The TOPAZ-1 study has provided valuable insights into the role of plasma circulating tumor DNA (ctDNA) testing in detecting clinically actionable alterations (CAAs) in advanced biliary tract cancer (BTC). While durvalumab plus gemcitabine and cisplatin (D+GC) has already demonstrated long-term survival benefits, this analysis explored whether plasma-based genomic profiling can effectively guide treatment decisions.
Findings showed a high concordance between plasma ctDNA and tumor tissue profiling, especially for key mutations like TP53, KRAS, and ARID1A. However, complex alterations in ERBB2 and FGFR2 were less frequently detected in ctDNA, suggesting that tumor tissue testing remains essential for a complete genomic assessment.
These results highlight the potential of ctDNA as a non-invasive tool for genomic profiling in BTC, with significant implications for precision oncology strategies. Further improvements in detecting complex alterations could enhance its clinical utility.
This research was made possible through the efforts of experts in the field, contributing to a deeper understanding of molecular profiling in BTC.
Read more: https://lnkd.in/egW9VRxT
